American Oriental Bioengineering, Inc.
Other OTCTotal Valuation
American Oriental Bioengineering, Inc. carries a market capitalization of 88.00, placing it among publicly traded companies globally. Its enterprise value stands at 93.65M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 88.00 |
| Enterprise Value | 93.65M |
Share Statistics
American Oriental Bioengineering, Inc. currently has 72,987.00 shares outstanding.
| Shares Outstanding | 72,987.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.03, and the price-to-book ratio stands at 0.18.
| PE Ratio | N/A |
| PS Ratio | 0.03 |
| PB Ratio | 0.18 |
| P/TBV Ratio | 0.03 |
| P/FCF Ratio | -0.60 |
| P/OCF Ratio | -0.13 |
Enterprise Valuation
| EV / Sales | 0.77 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
American Oriental Bioengineering, Inc. maintains a current ratio of 0.51, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 32.70, indicating elevated leverage, while an interest coverage ratio of -19.87 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.51 |
| Quick Ratio | 0.24 |
| Debt / Equity | 32.70 |
| Debt / EBITDA | -2.88 |
| Interest Coverage | -19.87 |
Financial Efficiency
| Return on Equity (ROE) | -132.78 |
| Return on Assets (ROA) | -19.60 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.41 |
Taxes
| Income Tax | 2.09M |
| Effective Tax Rate | N/A |
Stock Price Statistics
American Oriental Bioengineering, Inc.'s stock has gained approximately 139.99999% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 139.99999% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, American Oriental Bioengineering, Inc. generated 121.58M in revenue and converted that into -91.02M in net income, yielding earnings per share of -1,247.53. EBITDA reached -32.26M, while operating income came in at -44.42M.
| Revenue | 121.58M |
| Gross Profit | 39.62M |
| Operating Income | -44.42M |
| Pretax Income | -88.94M |
| Net Income | -91.02M |
| EBITDA | -32.26M |
| EBIT | -44.42M |
| Earnings Per Share (EPS) | -1,247.53 |
Balance Sheet
American Oriental Bioengineering, Inc. holds 3.23M in cash and equivalents against 92.77M in total debt, resulting in a net debt position of 89.54M. Total book value stands at 23.04M, with working capital of -61.54M providing operational flexibility.
| Cash & Cash Equivalents | 3.23M |
| Total Debt | 92.77M |
| Net Debt | 89.54M |
| Equity (Book Value) | 23.04M |
| Book Value Per Share | 315.72 |
| Working Capital | -61.54M |
Cash Flow
American Oriental Bioengineering, Inc. produced -31.24M in operating cash flow over the past twelve months. After subtracting -24.44M in capital expenditures, free cash flow totaled -55.68M - equivalent to -762.97 per share.
| Operating Cash Flow | -31.24M |
| Capital Expenditures | -24.44M |
| Free Cash Flow | -55.68M |
| FCF Per Share | -762.97 |
Margins
American Oriental Bioengineering, Inc. operates with a gross margin of 32.59, reflecting its pricing power and cost economics. The operating margin of -36.53 and net profit margin of -74.86 provide insight into operational efficiency.
| Gross Margin | 32.59 |
| Operating Margin | -36.53 |
| Pretax Margin | -73.16 |
| Profit Margin | -74.86 |
| EBITDA Margin | -26.53 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -681.45 |
| FCF Yield | -165.46 |
Stock Splits
American Oriental Bioengineering, Inc.'s most recent stock split took place on August 21, 2014 with a 501:1 split ratio.
| Last Split Date | 8/21/2014 |
| Split Ratio | 501:1 |
Scores
American Oriental Bioengineering, Inc. posts an Altman Z-Score of -0.23, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.23 |